Avid Bioservices
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$796.8M
-2.40
$150.45M
371
Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Recently from Cashu
Scinai Immunotherapeutics Enhances CDMO Capabilities at BIO-Europe Spring 2026 in Lisbon
Scinai Immunotherapeutics Strengthens Its Position at BIO-Europe Spring Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing therapies for inflammation and immunology, pre…
Abzena Recognized as Leader in ADC CDMO with Innovative ThioBridge® Platform
Abzena Solidifies Its Leader Status in ADC CDMO Space Abzena, a leading contract development and manufacturing organization (CDMO) specializing in complex biologics and bioconjugates, has recently bee…
Abzena Recognized as Leader in Antibody-Drug Conjugate Manufacturing by Frost & Sullivan
Abzena's Innovative Leadership in Antibody-Drug Conjugates Manufacturing Abzena, a contract development and manufacturing organization (CDMO) renowned for its expertise in complex biologics and biocon…
BioDlink Recognized as 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
BioDlink Emerges as a Leader in Biopharmaceutical Development BioDlink has recently been distinguished as the "Emerging CDMO of the Year" at the Asia-Pacific Biopharma Excellence Awards, organized by…